8-K: Krystal Biotech Subsidiary Jeune Aesthetics Reports Positive Phase 1 Results for Dcollet Wrinkle Treatment KB304

Jeune Aesthetics, a Krystal Biotech subsidiary, announced positive safety and efficacy results from its Phase 1 PEARL-2 study of KB304 for moderate to severe dcollet wrinkles, showing significant aesthetic improvements and a favorable safety profile.

Summary

• Jeune Aesthetics, a wholly-owned subsidiary of Krystal Biotech, announced positive safety and efficacy results from its randomized, double-blind, placebo-controlled Phase 1 PEARL-2 study of KB304 for moderate to severe wrinkles of the dcollet.
• KB304 is designed to deliver Type III collagen and elastin to restore skin naturally, addressing the underlying biology of aging skin.
• The study enrolled 19 subjects (12 KB304, 7 placebo), with 18 assessed through three months of follow-up.
• Investigator-reported Global Aesthetic Improvement Scale (GAIS) showed 100% of KB304-treated subjects had at least a one-point improvement in wrinkles at one, two, and three months, compared to 14.3% to 28.6% for placebo.
• Subject-reported GAIS indicated 72.7% to 90.9% of KB304 subjects had at least a one-point improvement, versus 14.3% for placebo.
• 81.8% of KB304 subjects reported improved satisfaction with their wrinkles' appearance three months post-treatment, compared to 14.3% of placebo subjects, as measured by the Subject Satisfaction Questionnaire (SSQ).
• Improvements in KB304 subjects were also observed across other skin attributes, including elasticity, crepiness, hydration, and radiance, with 100% investigator-reported improvement at all time points.
• The safety profile of KB304 was consistent with prior clinical experience, with all adverse events being mild-to-moderate and transient, primarily reported after the first dose and decreasing with subsequent doses.
• No severe or drug-related serious adverse events were reported in the study.

Sentiment

Score: 9

Explanation: The filing reports highly positive Phase 1 clinical trial results for a novel product candidate in a market with significant unmet needs. The efficacy data is strong, and the safety profile is favorable. This represents a significant de-risking event for the program and opens up a large market opportunity.

Positives

• KB304 demonstrated positive safety and efficacy results in the Phase 1 PEARL-2 study for moderate to severe wrinkles of the dcollet.
• 100% of KB304-treated subjects showed at least a one-point improvement in wrinkles as assessed by the investigator at one, two, and three months post-treatment.
• A high percentage of KB304 subjects (72.7% to 90.9%) reported at least a one-point improvement in wrinkles as assessed by themselves.
• 81.8% of KB304 subjects reported improved satisfaction with their wrinkles' appearance three months after treatment.
• KB304 treatment led to improvements across multiple skin attributes, including elasticity, crepiness, hydration, and radiance, with 100% investigator-reported improvement for KB304 subjects.
• The safety profile was favorable, with all adverse events being mild-to-moderate, transient, and decreasing with subsequent doses, and no severe or drug-related serious adverse events reported.

Risks

• Preliminary clinical data from a Phase 1 trial, which has a small sample size and limited follow-up, may not predict results in later-stage studies.
• Uncertainties are associated with regulatory review of clinical trials.
• Uncertainties exist regarding the availability or commercial potential of KB304.

Future Outlook

Jeune Aesthetics plans to prioritize the development of KB304, progressing it into Phase 2 development for the treatment of wrinkles in the dcollet. The company intends to meet with the FDA in the coming months to enable the initiation of the Phase 2 study, with a goal of starting it in the first half of 2026. Jeune has also completed the development and validation of a dcollet-specific photonumeric scale (JDWS) and plans to submit it to the FDA and align on the Phase 2 protocol in the second half of 2025. Additionally, Jeune will evaluate other potential indications for KB301 and expects to advance another product candidate into the clinic within the next 12-24 months.

Management Comments

• Marc Forth, Chief Executive Officer of Jeune, stated, "We believe that KB304 has the potential to revolutionize the treatment of wrinkles and skin quality by directly addressing the underlying biology of aging skin. KB304 is a truly unique product candidate, which we think will address a massive gap in the market two ways—being the first product candidate to directly address elastin and by doing so in the dcollet where there are no injectable products approved. Consumers are yearning for a solution that delivers natural looking results, and KB304 has the potential to restore the skin to a more youthful appearance."
• Suma Krishnan, President of Research & Development at Krystal Biotech, commented, "We believe KB304 has the potential to be a first-in-class treatment to deliver collagen and elastin directly to the skin. This study is the first randomized, double-blind, placebo-controlled trial to investigate the potential combinatorial benefits of COL3 and elastin supplementation when produced by the bodys own skin cells."

Industry Context

The announcement positions KB304 as a potentially revolutionary treatment in the aesthetic market, specifically targeting the dcollet region where no FDA-approved injectable products currently exist. Jeune Aesthetics aims to address a 'massive gap in the market' by directly replenishing key skin proteins (Type III collagen and elastin) to reverse the biology of aging skin, contrasting with existing aesthetic treatments like energy-based devices, fillers, and neurotoxins that primarily damage, add volume, or paralyze. The global skin rejuvenation market is substantial, valued at $24.6 billion in 2023 and projected to reach $44.5 billion by 2030, driven by aging demographics, increasing focus on beauty and wellness, the rise of 'prejuvenation,' and new demands from GLP-1 accelerated skin aging. Jeune's approach seeks to be an 'ideal primary tool for skin rejuvenation,' maintaining youthful skin naturally and potentially delaying or reducing the need for other aesthetic procedures.

Comparison to Industry Standards

• KB304 is positioned as a first-in-class treatment for dcollet wrinkles, as there are currently no FDA-approved injectable products specifically for this area, unlike other aesthetic treatments such as neurotoxins (e.g., Botox) and dermal fillers (e.g., Juvederm) which are widely approved for facial wrinkles.
• Unlike energy-based devices that damage skin to trigger a healing response, or fillers that add artificial volume, or neurotoxins that paralyze muscles, KB304's mechanism directly replenishes Type III collagen and elastin, addressing the underlying biological cause of skin aging.
• The study is noted as the first randomized, double-blind, placebo-controlled trial to investigate the combinatorial benefits of COL3 and elastin supplementation produced by the body's own skin cells, setting a new standard for research in this specific aesthetic application.

Stakeholder Impact

• Shareholders: Positive clinical trial results for a key pipeline asset are likely to increase investor confidence and potentially the company's valuation.
• Patients/Consumers: KB304 offers a potential new, biologically-driven treatment option for dcollet wrinkles, addressing an unmet aesthetic need.
• Employees: Positive clinical progress can boost morale and potentially lead to future growth and hiring.
• Regulatory Authorities: The company plans to engage with the FDA for Phase 2 protocol alignment, indicating ongoing regulatory interaction.

Next Steps

• Meet with the FDA in the coming months to discuss the KB304 clinical development program and enable initiation of the Phase 2 study.
• Submit the Jeune Dcollet Wrinkle Scale (JDWS) to the FDA and align on the Phase 2 study protocol in the second half of 2025.
• Initiate the Phase 2 study for KB304 in the first half of 2026.
• Evaluate other potential indications for KB301.
• Progress another product candidate into the clinic within the next 12-24 months.

Key Dates

Recommendation

The filing presents exceptionally strong Phase 1 data for KB304, demonstrating 100% investigator-reported efficacy and a favorable safety profile in a double-blind, placebo-controlled study. This de-risks the asset significantly. The dcollet market is identified as having a 'massive gap' with no FDA-approved injectables, positioning KB304 as a potential first-in-class treatment with a unique mechanism of action that addresses the underlying biology of aging skin. The global skin rejuvenation market is large and growing, indicating substantial commercial potential. The clear path to Phase 2 initiation and a robust pipeline further support a strong positive outlook for Krystal Biotech and its subsidiary Jeune Aesthetics.

Keywords

Krystal Biotech, Jeune Aesthetics, KB304, dcollet wrinkles, Phase 1 study, PEARL-2, gene therapy, collagen, elastin, aesthetic medicine, skin rejuvenation, clinical trial results, dermatology, biotechnology